Recent Updates
Recently added Catalysts
SRPT Negative Sentiment Score: 25/100

Sarepta Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SRPT

Key Takeaway: Sarepta Therapeutics, Inc. has been sued for securities law violations, as a class action lawsuit targets the company for alleged securities fraud impacting investors. The lawsuit pertains to alleged false statements regarding the safety of its gene therapy product, ELEVIDYS, and claims that these misleading statements could adversely affect ongoing trials and regulatory compliance. Investors have been notified of their rights and the opportunity to participate in the lawsuit until August 25, 2025.

Market Sentiment Analysis

CONCERNS & RISKS

  • Sarepta Therapeutics is facing a class action securities lawsuit due to alleged securities fraud.
  • The lawsuit claims that the company made false statements about the safety and efficacy of its gene therapy, ELEVIDYS.
  • The company may face regulatory scrutiny and potential halting of recruitment and dosing in its trials.

Full Press Release Details

NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team:
SRPT investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy’s present and expanded approvals; and (iv) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements.
WHAT'S NEXT? If you suffered a loss in Sarepta during the relevant time frame, you have until August 25, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 17th Floor

Tags

Frequently Asked Questions

What is the class action lawsuit against Sarepta Therapeutics about?

The lawsuit addresses alleged securities fraud affecting Sarepta investors from June 2023 to June 2025.

What drug is involved in the Sarepta lawsuit?

The lawsuit involves ELEVIDYS, a gene therapy for Duchenne, which allegedly posed safety risks.

What should I do if I lost money in Sarepta stocks?

If you suffered losses, you can request to be appointed as lead plaintiff by August 25, 2025.

Are there any costs to participate in the class action?

Participation in the class action incurs no out-of-pocket costs or fees for members.

What is Levi & Korsinsky's track record in securities litigation?

Levi & Korsinsky has secured substantial recoveries for investors and ranks among top firms in the U.S.

Last updated: Jul 3, 2025